Cyclerion Therapeutics Inc
NASDAQ:CYCN
Cyclerion Therapeutics Inc
NASDAQ:CYCN
Price:
3.02
USD
1.34%
Market Closed
Market Cap:
$13.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Cyclerion Therapeutics Inc
NASDAQ:CYCN
|
US |
Balance Sheet
Balance Sheet Decomposition
Cyclerion Therapeutics Inc
Cyclerion Therapeutics Inc
Balance Sheet Decomposition is not available for
Cyclerion Therapeutics Inc
Cyclerion Therapeutics Inc
Balance Sheet
Cyclerion Therapeutics Inc
Cyclerion Therapeutics Inc
Currency: USD
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
95
|
54
|
54
|
13
|
8
|
3
|
3
|
|
| Cash Equivalents |
0
|
0
|
0
|
95
|
54
|
54
|
13
|
8
|
3
|
3
|
|
| Total Receivables |
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Accounts Receivables |
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
1
|
5
|
4
|
1
|
1
|
0
|
0
|
0
|
|
| Total Current Assets |
0
|
1
|
1
|
101
|
59
|
56
|
15
|
8
|
4
|
5
|
|
| PP&E Net |
4
|
4
|
7
|
80
|
50
|
2
|
1
|
0
|
0
|
0
|
|
| PP&E Gross |
4
|
4
|
7
|
80
|
50
|
2
|
1
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
14
|
16
|
16
|
22
|
10
|
2
|
2
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
5
|
5
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
6
|
7
|
2
|
2
|
0
|
0
|
0
|
|
| Total Assets |
4
N/A
|
6
+41%
|
7
+35%
|
187
+2 420%
|
115
-38%
|
59
-49%
|
18
-69%
|
13
-26%
|
10
-28%
|
10
+4%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1
|
2
|
3
|
3
|
1
|
2
|
3
|
1
|
0
|
1
|
|
| Accrued Liabilities |
9
|
11
|
14
|
15
|
12
|
9
|
5
|
1
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
4
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
1
|
1
|
1
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
11
|
14
|
18
|
18
|
17
|
11
|
8
|
2
|
1
|
1
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
71
|
39
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
11
N/A
|
14
+32%
|
18
+27%
|
89
+398%
|
56
-37%
|
11
-80%
|
8
-32%
|
2
-73%
|
1
-65%
|
1
+24%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
0
|
0
|
0
|
86
|
163
|
215
|
259
|
264
|
267
|
271
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
183
|
223
|
263
|
270
|
276
|
276
|
280
|
|
| Other Equity |
7
|
9
|
10
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
7
N/A
|
9
-26%
|
10
-21%
|
98
N/A
|
60
-39%
|
48
-19%
|
11
-78%
|
11
+8%
|
9
-22%
|
9
+3%
|
|
| Total Liabilities & Equity |
4
N/A
|
6
+41%
|
7
+35%
|
187
+2 420%
|
115
-38%
|
59
-49%
|
18
-69%
|
13
-26%
|
10
-28%
|
10
+4%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
1
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
3
|
4
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
